Related Experiment Videos
Somatostatin analogues in the treatment of breast and prostate cancer
A Manni1, A E Boucher, L M Demers
1Department of Medicine, Milton S. Hershey Medical Center, Pennsylvania State University, Hershey 17033.
Abstract:
Newly developed somatostatin analogues may be useful agents in the treatment of breast and prostate cancer. Potential mechanisms of antitumor action include suppression of circulating levels of trophic hormones and growth factors as well as direct effects at the tumor level, potentially involving autocrine/paracrine mechanisms. Pilot clinical trials conducted in heavily pretreated women with advanced breast cancer indicate that SMS 201-995 (Sandostatin R) has minimal toxicity and moderately suppresses stimulated growth hormone secretion and basal somatomedin-C level. Somatostatin analogues have also been found to retard the growth of experimental prostate cancer, particularly when used in combination with LHRH analogues. The therapeutic efficacy of these compounds used alone or in combination with other agents in the treatment of breast and prostate cancer remains to be established in larger clinical trials involving less heavily pretreated patients.
Insights
New somatostatin analogues show potential for treating breast and prostate cancer by affecting hormone levels and tumor growth. Early trials suggest minimal toxicity and moderate suppression of growth factors, but further research is needed.
Area of Science:
- Endocrinology
- Oncology
Background:
- Somatostatin analogues are emerging as potential therapeutic agents for hormone-dependent cancers.
- Their mechanisms of action involve modulating trophic hormones, growth factors, and direct tumor effects.
Purpose of the Study:
- To evaluate the potential of somatostatin analogues in treating breast and prostate cancer.
- To assess their antitumor mechanisms and clinical efficacy.
Main Methods:
- Pilot clinical trials in advanced breast cancer patients.
- Studies on experimental prostate cancer models, including combination therapies.
Main Results:
- SMS 201-995 (Sandostatin) demonstrated minimal toxicity in breast cancer patients.
- Moderate suppression of growth hormone and somatomedin-C levels was observed.
- Somatostatin analogues showed efficacy in retarding experimental prostate cancer growth, especially with LHRH analogues.
Conclusions:
- Somatostatin analogues hold promise for breast and prostate cancer treatment.
- Further large-scale clinical trials are necessary to confirm efficacy in less pretreated patient populations.